CELG News and Press, Celgene Corporation From 11/12/19

Investment Thesis Imetelstat of Geron Corporation ( GERN ), with its superior therapeutic efficacy, as proven in a phase 2 trial, looks promising for a largely under-served MDS (myelodysplastic syndromes) market. With only a single drug in the pipeline focusing on two rare forms of blood c...

Privately held Skyhawk Therapeutics enters into a second collaboration agreement with an affiliate of Celgene ( CELG +0.4% ) aimed at identifying targets in autoimmune disorders, oncology and immuno-oncology leveraging Skyhawk's SkySTAR technology platform. More news on: Celgene Corpor...

Celgene to receive exclusive options to license a number of Skyhawk's product candidates directed to multiple high-value autoimmune disorder, oncology, and immuno-oncology targets.  Skyhawk to receive $80 Million upfront payment and is eligible for potential milestone payments...

No matter how you look at it, Bristol-Myers Squibb (NYSE: BMY) claims an attractive dividend. Its yield currently stands north of 2.8%. The big pharma company has a payout ratio of only 47%, giving it plenty of flexibility to keep the solid dividends coming. And Bristol-Myers Squibb's div...

REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients Approval of REBLOZYL marks the first FDA-approved treatment for anemia in beta thalassemia Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (N...

It's been an up-and-down kind of year so far for Acceleron Pharma (NASDAQ: XLRN) . In September, the biotech announced disappointing phase 2 results for ACE-083 in treating facioscapulohumeral muscular dystrophy (FSHD) and scrapped its FSHD program. However, Acceleron's shares have rebounde...

Nearly 70 abstracts, including more than 20 oral presentations highlight diverse portfolio of innovative treatment modalities, including potentially transformative cell therapies Celgene Corporation (NASDAQ: CELG) today announced data from nearly 70 Company-sponsored, global alliance a...

China spent $137 billion on healthcare in 2018 and could spend up to $170 billion annually by 2023. Two exciting biotech companies ,  BeiGene (NASDAQ: BGNE)  and Zai Lab (NASDAQ: ZLAB) , allow investors an opportunity to get in on the action while it's still early. And why ...

By Breakingviews Amgen's (AMGN) Chinese deal could be good medicine. The pharma giant is paying around $2.7 billion for a 20.5% stake in biotech group BeiGene (BGNE). Splurging on a minority stake in a pre-profit outfit that just fought off a short-seller is hard to stomach. But a partners...

The spread on the Bristol-Myers (BMY) and Celgene (CELG) deal has been rapidly closing recently. The gross spread is a negative 1.28%. I've written a ton about this deal in the past, and it is my largest M&A position. The spread is finally getting so tight that you need to ascribe value to...